Originally Posted by
Aimless
I don't think the expectation is that developing countries are gonna reverse-engineer the vaccine production processes from scratch; the hope is that waivers will help remove obstacles such as licensing requirements. In the short-to-medium term, this would help eg. India and its neighbouring countries start up production at more sites, which can then help supply the region with vaccines more effectively. Most of the requisite knowledge is already available in the region, as companies like AstraZeneca and J&J have already started up production in India, partnering with proven local biotech firms; retasking other plants in the region to produce finished vaccine product is about as feasible as it is to do so in eg. Europe, and it will be useful to do so even if it takes several more months to get production rolling—because these extremely populous regions will need to keep producing and administering vaccines at breakneck speed at least for the remainder of the year, and probably well into 2022, even after the global pandemic is determined to be over. In the medium-to-long term, the same freedom from licensing requirements would help these countries respond more swiftly to future outbreaks, forestalling future disasters driven by new variants. Wiggins's company and their product line are a very different matter, for a large number of reasons.